Determining Your Patient's Eligibility
The Oncotype DX® Breast Recurrence Score™ provides comprehensive and actionable direction across the spectrum of ER-positive, invasive breast cancer biology, predicting the likelihood of adjuvant therapy benefit as well as your patient’s 10-year risk of distant recurrence. This information will help to guide your recommendation to personalize treatment for each of your patients.
The Breast Recurrence Score is intended for use in all newly diagnosed patients with invasive breast cancer who are:
- Node-negative or node-positive (1-3)
FOR ALL EARLY-STAGE, ER-POSITIVE, HER2-NEGATIVE,
NODE-NEGATIVE, AND NODE-POSITIVE (1–3) PATIENTS
WITH INVASIVE BREAST CANCER
By testing every eligible patient after surgery but before you discuss her treatment
plan, you can make recommendations with increased insight and confidence.
Next: Genomic Health Leadership